The multi-societal European consensus on the terminology, diagnosis and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE

Ajith K. Siriwardena*, Alejandro Serrablo, Åsmund A. Fretland, Stephen J. Wigmore, Jose M. Ramia-Angel, Hassan Z. Malik, Stefan Stättner, Kjetil Søreide, Oded Zmora, Martijn Meijerink, Nikolaos Kartalis, Mickaël Lesurtel, Cornelis Verhoef, Anita Balakrishnan, Thomas Gruenberger, Eduard Jonas, John Devar, Saurabh Jamdar, Robert Jones, Mohammad A. HilalBodil Andersson, Karim Boudjema, Saifee Mullamitha, Laurents Stassen, Bobby V.M. Dasari, Adam E. Frampton, Luca Aldrighetti, Gianluca Pellino, Pamela Buchwald, Bengi Gürses, Nir Wasserberg, Birgit Gruenberger, Harry V.M. Spiers, William Jarnagin, Jean Nicholas Vauthey, Norihiro Kokudo, Sabine Tejpar, Andres Valdivieso, René Adam, Hauke Lang, Martin Smith, Michelle L. deOliveira, Anya Adair, Stefan Gilg, Rutger Jan Swijnenburg, Joris Jaekers, Santhalingam Jegatheeswaran, Carlijn Buis, Rowan Parks, Maximilian Bockhorn, Joint E-AHPBA/ESSO/ESCP/ESGAR/CIRSE 2022 Consensus on colorectal cancer with synchronous liver metastases

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Contemporary management of patients with synchronous colorectal cancer and liver metastases is complex. The aim of this project was to provide a practical framework for care of patients with synchronous colorectal cancer and liver metastases with a focus on terminology, diagnosis and management. Methods: This project was a multi-organisational, multidisciplinary consensus. The consensus group produced statements which focused on terminology, diagnosis and management. Statements were refined during an online Delphi process and those with 70% agreement or above were reviewed at a final meeting. Iterations of the report were shared by electronic mail to arrive at a final agreed document comprising twelve key statements. Results: Synchronous liver metastases are those detected at the time of presentation of the primary tumour. The term “early metachronous metastases” applies to those absent at presentation but detected within 12 months of diagnosis of the primary tumour with “late metachronous metastases” applied to those detected after 12 months. Disappearing metastases applies to lesions which are no longer detectable on MR scan after systemic chemotherapy. Guidance was provided on the recommended composition of tumour boards and clinical assessment in emergency and elective settings. The consensus focused on treatment pathways including systemic chemotherapy, synchronous surgery and the staged approach with either colorectal or liver-directed surgery as first step. Management of pulmonary metastases and the role of minimally invasive surgery was discussed. Conclusions: The recommendations of this contemporary consensus provide information of practical value to clinicians managing patients with synchronous colorectal cancer and liver metastases.
Original languageEnglish
Pages (from-to)985-999
Number of pages15
JournalHPB
Volume25
Issue number9
DOIs
Publication statusPublished - 1 Sept 2023

Cite this